fda compounding semaglutide news september 2025 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of GLP-1 medications like and tirzepatide, signaling a major shift in how these FDA Drug Recalls and Warnings:

Patients who inadvertently use expired semaglutide should: Monitor blood glucose levels closely (for diabetes patients) to detect any loss of glycemic control Watch for injection site reactions such as increased redness, warmth, swelling, or pain that could indicate infection Contact their healthcare provider to report the incident and obtain guidance on next steps Obtain a fresh supply and resume treatment with properly stored, unexpired medication Healthcare providers should emphasize the importance of adhering to expiration guidelines

Preventing breakdown in inflamed GI lining (gastric ulcers, colitis models)

What the numbers actually look like These are approximate 2026 figures

Our goal is ensuring that any treatment you choose, including GLP-1 medications, moves you closer to food freedom, not further from it

the difference is the formulation and the testing the manufacturer or compounder has done